ZYDUSLIFEBSEZydus Lifesciences LtdHighPositive
Announced Tue, 19 May · 19:49 IST

Board resolution - Buyback

Buyback Premium Above 10pctCorporate Actions View source PDF

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.9%1-day move
₹1017.70
prior close
₹1066.15
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.8+0.7+2.0+1.9+2.1+5.2+5.8+6.8+7.0+8.9+6.7+12.9
Up moveDown movePending
AI summary

Zydus Lifesciences Limited's Board has approved a buyback of up to 95,65,217 equity shares (approximately 0.95% of total paid-up capital) at INR 1,150 per share. The maximum buyback amount is INR 1,100 crore, representing 5.16% and 3.84% of standalone and consolidated free reserves respectively as of March 31, 2026. The buyback will be conducted via tender offer through NSE (designated stock exchange) on a proportionate basis, with 15% reserved for small shareholders. The record date is May 29, 2026, and the buyback must be completed within one year from the board meeting date. ICICI Securities is appointed as manager and buying broker, with MUFG Intime as the registrar. Promoter and promoter group are also eligible to participate.

Likely market impact

The buyback offers shareholders a chance to exit at INR 1,150 per share, representing a return of capital. With the company confirming no grounds for insolvency and adequate financial resources, this is positive for shareholders seeking liquidity at the offer price.